Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns.
Bueno H, Sinnaeve P, Annemans L, Danchin N, Licour M, Medina J, Pocock S, Sánchez-Covisa J, Storey RF, Jukema JW, Zeymer U, Van de Werf F; EPICOR Investigators.
Bueno H, et al.
Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):3-12. doi: 10.1177/2048872614565912. Epub 2015 Jan 5.
Eur Heart J Acute Cardiovasc Care. 2016.
PMID: 25561688
STEMI patients more often received pre-hospital anti-thrombotics, and prasugrel, GP IIb/IIIa inhibitors and UFH in-hospital (all p < 0.001). More NSTE-ACS patients received clopidogrel, single anti-platelet therapy, and fondaparinux (all p < 0.001). ...
STEMI patients more often received pre-hospital anti-thrombotics, and prasugrel, GP IIb/IIIa inhibitors and UFH in-hospital (all p &l …